Developing breakthrough platforms for long acting non-viral
gene therapy for ocular diseases

Eyevensys S.A.S. is a privately held biotechnology company developing a game changing approach to express therapeutic proteins in situ for the treatment of major ophthalmic diseases.

Eyevensys Unique Approach is based on:

• The Electro-Transfection of therapeutic plasmids in the Ciliary muscle
• A Proprietary injection and electro-tranfection device allowing accurate local treatment
• Reliance on Therapeutic Proteins with well-established efficacy records

The ciliary muscle is a ring of smooth muscle in the eye's middle layer (vascular layer) that controls accommodation for viewing objects at varying distances and regulates the flow of aqueous humour. It changes the shape of the lens within the eye. It is a smooth muscle devoid of neuronal cells. The location near the eye surface allows a minimally invasive procedure. It is also at the crossroads between the anterior and posterior segments of the eyes, and protein secretion can be achieved in both eye segments.
Consequently, the ciliary muscle constitutes an ideal transfection target to produce intraocular therapeutic proteins.


Eyevensys